Show simple item record

dc.contributor.authorDaniel, Shawnée
dc.contributor.authorSvoboda, Leanne
dc.contributor.authorChen, Justin
dc.date.accessioned2021-05-03T18:43:31Z
dc.date.available2021-05-03T18:43:31Z
dc.date.issued2021-03-31
dc.identifier.urihttp://hdl.handle.net/10713/15560
dc.description.abstractOBJECTIVES An adverse consequence of primarily soybean oil–based parenteral nutrition is the development of intestinal failure–associated liver disease (IFALD), defined as bilirubin ≥ 2 mg/dL. Fish oil– containing lipid emulsion products, such as soybean oil, medium-chain triglycerides, olive oil, fish oil lipid injectable emulsion (SMOF-ILE), have been shown to be beneficial in patients at risk of developing IFALD. This study aimed to review the safety profile of SMOF-ILE and soybean oil–based lipid injectable emulsion (SO-ILE) in regard to liver function and cholestasis in the pediatric and neonatal population. METHODS A retrospective review was performed for patients who received SO-ILE or SMOF-ILE over a 3-year period. Patients < 18 years of age who received at least 2 weeks of either product were included. The primary endpoints were 2 consecutive bilirubin readings ≥ 2 mg/dL that were separated by at least 1 week and time to first bilirubin ≥ 2 mg/dL. Secondary endpoints included assessment of select laboratory values (i.e., aspartate aminotransferase, alanine aminotransferase, triglycerides, serum creatinine, serum sodium, coagulation laboratory test, albumin) up to 6 months while on intravenous lipid products. Ursodiol use and mortality were also noted. RESULTS There was a higher prevalence of IFALD in pediatric patients receiving SO-ILE than those who received SMOF-ILE (32% vs 12%, p = 0.03). There was no detectable difference in the time it took for IFALD to develop (19 days vs 15 days, p = 0.08). CONCLUSION In our cohort of pediatric and neonatal patients, the incidence of IFALD was higher with SOILE than with SMOF-ILE. ABBREVIATIONS ALT, alanine aminotransferase, AST, aspartate aminotransferase, EFAD, essential fatty acid deficiency, FDA, US Food and Drug Administration, GI, gastrointestinal, IFALD, intestinal failure–associated liver disease, ILEs, lipid injectable emulsions, INR, international normalized ratio, NICU, neonatal intensive care unit, PN, parenteral nutrition, SMOF-ILE, soybean oil, medium-chain triglycerides, olive oil, fish oil lipid injectable emulsion, SO-ILE, soybean oil–based lipid injectable emulsion. © Pediatric Pharmacy Association. All rights reserved.en_US
dc.description.urihttps://doi.org/10.5863/1551-6776-26.3.258en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021239/en_US
dc.language.isoenen_US
dc.publisherPediatric Pharmacy Advocacy Group, Inc.en_US
dc.relation.ispartofJournal of pediatric pharmacology and therapeuticsen_US
dc.rightsCopyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.en_US
dc.subjectadverse effecten_US
dc.subjectcholestasisen_US
dc.subjectintestinal failure–associated liver diseaseen_US
dc.subjectlipid emulsionen_US
dc.subjectlipidsen_US
dc.subjectparenteral nutritionen_US
dc.subjectpediatricsen_US
dc.titleLiver Function in Pediatric Recipients: A Comparison of Intralipid and Smoflipiden_US
dc.typeArticleen_US
dc.identifier.doi10.5863/1551-6776-26.3.258
dc.identifier.pmid33833627
dc.source.volume26
dc.source.issue3
dc.source.beginpage258
dc.source.endpage264
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record